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The reason why scan 3 correlates better to scan 2 is due to 
the shorter timespan between scan 2 and scan 3 compared to 
the timespan between scan 1 and scan 2. In this timespan the 
patients continuously produced urine. 
The bladder scanner measured the fluid volume inside the 
bladder and the bladder volume on the planning CT included 
the bladder wall, which of course introduce a systematic 
difference between the 2 measurements 
The overall changes in bladder volume over time revealed 
that the ultrasound bladder scan should be performed before 
15-20 minutes of the planning CT. Within this timeframe the 
bladder volume would not differ more than 150 ml 
Conclusions: The data shows, that we can rely on, and use 
the measures from the ultrasound bladder scan. Therefore, 
the bladder scan is a non-ionizing god tool, to optimize 
bladder volume in the everyday work flow. 
Our futures plans involve monitoring of inter observer 
differences in bladder volume measurements and how to 
incorporate our findings in the treatment executive process. 
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Purpose/Objective: Oral cavity (OC) is an important organ at 
risk (OAR) to keep in mind when planning radiotherapy 
treatment in locally advanced head and neck cancer patients. 
The quality of life in these patients can be diminished 
because of the mucositis profile, reducing the tolerance and 
efficacy of the therapy. Lowering the D mean and D max 
constraints to the OC without compromise the prescribe dose 
to the PTV can be achieved helping to decrease the risk of 
sever mucositis (Figure 1). There are no consensuses that 
demonstrate a better way of contour the OC as OAR. The 
objective of this study is to investigate how the method we 
used to contour the OC influences on dosimetry without 
compromising the treatment compliance and reduces the risk 
of severe mucositis. 
Figure 1. Oropharyngeal mucositis secondary to chemo-
radiotherapy without contouring OC as OAR. 
 
 
 
Materials and Methods: Nineteen patients with locally 
advance head and neck cancer treated with Intensity 
Modulated Radiotherapy (IMRT) techniques were analysed in 
this study. Treatment was designed according to 
international recommendations utilising IMRT technique with 
7 fields and dynamic multileaf collimator, delivering dose 
between 66 and 70 Gy to the PTV. The Monaco treatment 
planning system with Monte Carlo algorithm was used. The 
same physician made the contouring of the PTV volume and 
the OC. The oral cavity included: hard palate mucosa, floor 
of the mouth, orbicular muscle and lips, upper and lower 
teeth and gingiva, oral vestibule and the ventral 2/3 portion 
of the tongue.Patients were followed weekly by the physician 
recording and classifying the grade of mucositis in two 
groups, group A: asymptomatic or mild ulcers and group B: 
severe ulcers or mayor bleeding pseudo membrane. Oral 
cavity D mean, D max, V50Gy, V45Gy, V40Gy, V35Gy, V30Gy, 
V25Gy and V20Gy were recorded and compared. We used a 
standard statistical analysis to describe the D mean, D max 
and volumes with the grade of mucositis appearance. We 
have compared our results with similar published series. 
Results: The PTV median prescribed dose was 67Gy (range: 
66-70Gy) without losing tighter values of D max: 38.3Gy 
(range: 32-52) and D mean: 18Gy (range: 10-26Gy). In the 
group A, 15 patients (78.9%) were assessed with mucositis 
toxicity grade ≤2 and in-group B, only 4 patients (21%) 
reached a mucositis toxicity grade ≥3 with no severe 
complications. In the 19 cases the OC volumes mean was 
96.4cc accomplishing lower doses in the oral cavity has an 
organ at risk. We also evaluated the V20, V25, V30, V45 and 
V50 of the OC. 
(Table 1) 
Age (years) 57 (range: 45-84) 
Gender 
Male 
Female 
12 
7 
Karnofsky status % 90 (80-100) 
Prescribed dose 67Gy (range 66-70) 
D Mean 18 Gy (range 10-26) 
D max 38Gy (range 32-52) 
Volume 96.44cc (range 49-154) 
V20 Gy OC 48% 
V25Gy OC 26% 
V30 Gy OC 7% 
V35 Gy OC 1.5% 
V40 Gy OC 0.44% 
V45 Gy OC 0.16% 
V50Gy OC 0.010% 
Mucositis groups 
A 
B 
15 (78%) 
4 (21%) 
 
Table 1 Clinical and dosimetric results for the OC contour as 
OAR.  
 
Conclusions: This descriptive study shows contouring the OC 
in a tighter way can be achieved without risking PTV dose 
prescribe, the D mean and D max. Also features lesser D max 
D mean in the OC comparing the publications available, 
reaching more restrictive constrains dose and lowering sever 
mucositis presentation. More research is needed to compare 
different methods to contour the oral cavity to obtain a 
lower mucositis profile. 
   
 
 
 
